Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase
- PMID: 20564343
- DOI: 10.1002/mc.20637
Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase
Abstract
Metformin is widely used for the treatment of diabetes mellitus. Adenosine monophosphate-activated protein kinase (AMPK) is known to be activated by metformin and to inhibit the mammalian target of rapamycin (mTOR) pathway. The mTOR pathway plays an important role in the protein translational machinery and cell proliferation. We examined the effect of metformin on the suppression of colorectal carcinogenesis in chemical carcinogen-induced models. Seven-wk-old BALB/c mice were intraperitoneally (i.p.) injected with azoxymethane (AOM, 10 mg/kg) and then treated with or without metformin (250 mg/kg/d) for 6 wk (for the investigation of aberrant crypt foci [ACF] formation) or 32 wk (for polyp formation). We next investigated colonic epithelial proliferation using bromodeoxyuridine (BrdU) and the proliferating cell nuclear antigen (PCNA) labeling indices. Furthermore, to examine the indirect effect of metformin, the insulin resistance status and the serum lipid levels were assessed. Treatment with metformin significantly reduced ACF formation. The effect of metformin on colon polyp inhibition was relatively modest. No significant difference in body weight or glucose concentration was observed. The BrdU and PCNA indices decreased in mice treated with metformin. A Western blot analysis revealed that the phosphorylated mTOR, S6 kinase, and S6 protein levels in the colonic mucosa decreased significantly in mice treated with metformin. In conclusion, metformin suppresses colonic epithelial proliferation via the inhibition of the mTOR pathway through the activation of AMPK. As metformin is already used daily as an antidiabetic drug, it might be a safe and promising candidate for the chemoprevention of colorectal cancer.
Similar articles
-
Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial.Cancer Prev Res (Phila). 2010 Sep;3(9):1077-83. doi: 10.1158/1940-6207.CAPR-10-0186. Epub 2010 Sep 1. Cancer Prev Res (Phila). 2010. PMID: 20810669 Clinical Trial.
-
Colon epithelial proliferation and carcinogenesis in diet-induced obesity.J Gastroenterol Hepatol. 2013 Dec;28 Suppl 4:41-7. doi: 10.1111/jgh.12240. J Gastroenterol Hepatol. 2013. PMID: 24251703 Review.
-
Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase.Endocr Relat Cancer. 2010 Jun 1;17(2):351-60. doi: 10.1677/ERC-09-0252. Print 2010 Jun. Endocr Relat Cancer. 2010. PMID: 20228137
-
Egg yolk proteins suppress azoxymethane-induced aberrant crypt foci formation and cell proliferation in the colon of rats.Nutr Res. 2009 Jan;29(1):64-9. doi: 10.1016/j.nutres.2008.12.003. Nutr Res. 2009. PMID: 19185779
-
Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin.Expert Rev Mol Diagn. 2010 May;10(4):509-19. doi: 10.1586/erm.10.22. Expert Rev Mol Diagn. 2010. PMID: 20465505 Review.
Cited by
-
Metformin suppresses pancreatic tumor growth with inhibition of NFκB/STAT3 inflammatory signaling.Pancreas. 2015 May;44(4):636-47. doi: 10.1097/MPA.0000000000000308. Pancreas. 2015. PMID: 25875801 Free PMC article.
-
Metformin and other biguanides in oncology: advancing the research agenda.Cancer Prev Res (Phila). 2010 Sep;3(9):1060-5. doi: 10.1158/1940-6207.CAPR-10-0175. Epub 2010 Sep 1. Cancer Prev Res (Phila). 2010. PMID: 20810670 Free PMC article. Review.
-
Metformin: a potential therapeutic agent for recurrent colon cancer.PLoS One. 2014 Jan 20;9(1):e84369. doi: 10.1371/journal.pone.0084369. eCollection 2014. PLoS One. 2014. PMID: 24465408 Free PMC article.
-
Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis.Cancer Prev Res (Phila). 2012 Apr;5(4):544-52. doi: 10.1158/1940-6207.CAPR-11-0228. Epub 2012 Mar 31. Cancer Prev Res (Phila). 2012. PMID: 22467080 Free PMC article.
-
Does use of metformin protect against cancer in Type 2 diabetes mellitus?J Endocrinol Invest. 2012 Feb;35(2):231-5. doi: 10.1007/BF03345423. J Endocrinol Invest. 2012. PMID: 22490993 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous